Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model.
J Antimicrob Chemother
; 60(3): 594-8, 2007 Sep.
Article
en En
| MEDLINE
| ID: mdl-17606481
ABSTRACT
OBJECTIVES:
Ceftobiprole is a novel broad-spectrum cephalosporin with good in vitro activity against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. The objective of this study was to assess the in vivo activity of ceftobiprole against four strains of E. faecalis, including beta-lactamase- producing (Bla+) and vancomycin-resistant strains.METHODS:
Mice were infected intraperitoneally with strains of E. faecalis (i) the Bla+ strain HH22; (ii) two vancomycin-resistant strains (TX2484 and V583); and (iii) OG1RF (a laboratory strain), using 10 x the LD50 for each strain. Ceftobiprole doses of 25, 12.5 and 6.25 mg/kg (single doses) and ampicillin 50, 25, 12.5 and 6.25 mg/kg (single and double doses) were administered subcutaneously immediately after bacterial challenge and mice were monitored for 96 h.RESULTS:
All four E. faecalis had ceftobiprole MICsCONCLUSIONS:
Ceftobiprole had comparable in vivo activity to that of ampicillin against vancomycin-resistant and ampicillin-susceptible strains of E. faecalis in the mouse peritonitis model. Ceftobiprole was superior in vivo to ampicillin against the Bla+ strain HH22. Our data support the further study of ceftobiprole as a therapeutic agent in humans infected with E. faecalis.
Buscar en Google
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Plantas_medicinales
Asunto principal:
Peritonitis
/
Cefalosporinas
/
Infecciones por Bacterias Grampositivas
/
Enterococcus faecalis
/
Antibacterianos
Idioma:
En
Revista:
J Antimicrob Chemother
Año:
2007
Tipo del documento:
Article
País de afiliación:
Estados Unidos